Produced in collaboration with Amyloidosis Support Groups.
Support for this patient education program was provided by Alnylam Pharmaceuticals.
hATTR amyloidosis is a rare condition that occurs when an abnormal protein called amyloid builds up in tissue or organs like the heart, nervous system and digestive tract.
Watch on demand today to hear from doctors, advocates and people living with hATTR amyloidosis to learn about:
- Understanding that amyloidosis can be a genetic condition
- Determining with your doctor whether you or your loved one should seek genetic testing for hATTR amyloidosis
- Communicating with family members the importance of genetic testing if a direct relative has already been diagnosed with a genetic form of amyloidosis
- Recognizing symptoms associated with hATTR amyloidosis
Intended for U.S. Audiences Only.
Dr. Janice Wiesman, MD
NYU Langone Health
Janice Wiesman, MD, FAAN, was a clinical associate professor of neurology at NYU School of Medicine, attending physician at Bellevue Hospital in New York, New York, and adjunct assistant professor of neurology at Boston University School of Medicine in Boston, Massachusetts. She had been the neurologist for the Boston University Amyloidosis Treatment and Research Center for over 20 years and had participated in clinical trials for familial amyloidosis. Dr Wiesman was a speaker for the National Amyloidosis Support Group, a member of the Advocacy Committee of the American Academy of Neurology, and the author of Peripheral Neuropathy: What It Is and What You Can Do to Feel Better, 2016, Johns Hopkins Press.
Dr. Frederick Ruberg, MD
Boston Medical Center
Frederick L. Ruberg, MD, is the associate professor of medicine and radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC) in Boston, Massachusetts. His research focuses on the application of non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. Dr. Ruberg serves as senior cardiologist in the BU Amyloidosis Center, associate chief for academic affairs, Section of Cardiovascular Medicine, co-director of the Cardiovascular Medicine Fellowship program, and director of the cardiac MRI program at BMC. He is an associate editor of Circulation: Cardiovascular Imaging and a fellow of the American Heart Association. Dr. Ruberg attended the University of Pennsylvania School of Medicine in Philadelphia.
Emily Brown, MGC, CGC
Johns Hopkins Hospital
Emily Brown is a certified genetic counselor in the Center for Inherited Heart Diseases at Johns Hopkins Hospital in Baltimore, Maryland. Her specialty is patients with hereditary transthyretin amyloidosis, and she has participated in multiple research studies and drug trials related to this condition. Emily has a passion for increasing patient and healthcare professional knowledge about this condition, which has prompted her to present at multiple national meetings, most recently at the Heart Failure Society of America Scientific Sessions in Philadelphia, Pennsylvania.
Amyloidosis Support Groups
Muriel Finkel, co-founder of Amyloidosis Support Groups (ASG), was a caregiver for her uncle, who had amyloidosis, in the 1990s and early 2000s. Muriel and her husband started ASG in 2004 as a way for patients, caregivers, and those who had lost loved ones to amyloidosis to connect over their experiences. The ASG has grown to more than 50 meetings a year in 30 cities as well as into a passion for Muriel. The ASG has touched the lives of more than 5,000 amyloidosis patients and loved ones in the United States and Canada through face-to-face meetings and Facebook support groups. The ASG, at the request of several amyloidosis physicians, has recently started a patient registry to help researchers and patients find out more about their disease.
Sean Riley, adjunct professor of Nuclear Engineering Technology, resides in Boston, Massachusetts. He began experiencing disease symptoms of numbness in his left shin and foot several years ago. Over the next three years, Sean lost approximately 80 pounds of weight and started experiencing symptoms of lightheadedness. After moving to Abu Dhabi and experiencing a fainting episode, a cardiologist advised him to return to the United States for treatment. Sean’s condition, hereditary ATTR (hATTR) amyloidosis, was confirmed at Brigham and Women’s Hospital in February 2019, and his treatment commenced in May. The progression of his disease appears to be halted. Sean wants to help educate the medical community so future patients can be diagnosed and treated at a much earlier stage of disease progression.